These forwardlooking statements include statements relating to our future operations financial performance and projections business plans market opportunities priorities and research and development programs including the design of the AAVrh74 vector to systematically and robustly deliver treatment to skeletal muscle making it an ideal candidate to treat muscle disease and expected plans and milestones including our plan to initiate pivotal trial SRP9001301 Study 301 or EMBARK in September of 2021 in the United States and globally and our plan to move as fast as science will permit to confirm the benefits of SRP9001 and if successful to rapidly advance this therapy to waiting Duchenne patients around the world